Maria Rovithi

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing

Maria Rovithi, Amir Avan, Niccola Funel et al. · Scientific Reports · 2017 · 88 citations · Full text

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Kristy J. Gotink, Maria Rovithi, Richard R. de Haas et al. · Cellular Oncology · 2015 · 57 citations · Full text

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

Emmanouil Kontopodis, Dora Hatzidaki, Ioannis Varthalitis et al. · Journal of Chemotherapy · 2013 · 48 citations

Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial

Ourania Katopodis, Aris Polyzos, Nikolaos Kentepozidis et al. · Cancer Chemotherapy and Pharmacology · 2010 · 28 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +9

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

Richard J. Honeywell, Ietje Kathmann, Elisa Giovannetti et al. · Cancers · 2020 · 23 citations · Full text